PCVX vs BNTX vs PFE vs MRNA

For growth investors, BioNTech SE (BNTX) is the stronger pick with 0.

2% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Pfizer Inc. (PFE) offers the better valuation at 18. 9x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Vaxcyte, Inc. (PCVX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Vaxcyte, Inc.

(PCVX) delivered a total return of +222. 2%, compared to -65. 7% for Moderna, Inc. (MRNA). Over 10 years, the gap is even starker: BNTX returned +575. 8% versus PFE's +28. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 49β versus Moderna, Inc. 's 1. 81β — meaning MRNA is approximately 267% more volatile than PFE relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioNTech SE (BNTX) is pulling ahead at 0.

2% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Moderna, Inc. grew EPS 21. 7% year-over-year, compared to -62. 8% for BioNTech SE. Over a 3-year CAGR, PFE leads at -14. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — BNTX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PCVX: 56.

6% to $83. 00.

In this comparison, PFE (6.

7% yield) pays a dividend. PCVX, BNTX, MRNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 6. 7% yield). Moderna, Inc. (MRNA) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +28. 5%, MRNA: +192. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCVX is a small-cap quality compounder stock; BNTX is a mid-cap quality compounder stock; PFE is a mid-cap income-oriented stock; MRNA is a mid-cap quality compounder stock. PFE pays a dividend while PCVX, BNTX, MRNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.